Exploratory Study to Evaluate the Combined Effect of CBM588 in Platinum-Based Chemotherapy + Pemetrexed + Pembrolizumab Therapy for Non-Small Cell Lung Cancer (MIYABRO study)

未提供0 个研究点目标入组 20 人开始时间: 待定

适应症

试验速览

阶段: 不适用
状态: 招募中
入组人数: 20

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Single Arm Study

入排标准

年龄范围: 18age old over 至 No limit（—）
性别: All

入选标准

•Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC).
•Untreated, advanced, or recurrent non-squamous NSCLC. Measurable lesions are not required.
•Patients presenting with diarrhea, abnormal bowel movements, anorexia, abdominal pain, abdominal distension, nausea, or vomiting at the time of informed consent.
•Age 18 years or older at the time of informed consent.
•ECOG Performance Status (PS) of 0 or 1 at the time of informed consent.
•No active concurrent malignancy.
•Laboratory values within 14 days prior to registration must meet all of the following:
•a. Absolute neutrophil count: 1,500 / uL or higher
•b. Platelet count: 100,000 / uL or higher
•c. Total bilirubin: 1.5 mg/dL or lower
•d. AST: 100 U/L or lower (200 U/L or lower if liver metastasis is present)
•e. ALT: 100 U/L or lower (200 U/L or lower if liver metastasis is present)
•f. Creatinine clearance: 45 mL/min or higher
•g. SpO2 on room air: 92 percent or higher
•Tumor PD-L1 (22C3) Tumor Proportion Score (TPS) less than 50 percent.
•Negative for activating EGFR mutations (exon 19 deletion, exon 21 L858R, G719X, L861Q, S768I, or combinations with T790M), and negative or unknown for ALK fusion, ROS1 fusion, BRAF V600E, MET exon 14 skipping, and RET fusion.
•Note: NTRK fusion, KRAS G12C mutation, and HER2 mutation are eligible.
•No active autoimmune disease and no history of chronic or recurrent autoimmune disease requiring systemic treatment.
•Exceptions include well-controlled type 1 diabetes mellitus, thyroid disorders treated with oral medication only, and autoimmune skin conditions not requiring systemic therapy.
•Written informed consent has been obtained from the patient.

排除标准

•Stage IA to IIIA NSCLC in which lobectomy is possible.
•Presence of symptomatic pericardial effusion.
•Symptoms of superior vena cava syndrome requiring urgent radiation therapy.
•Uncontrolled serious cardiovascular disease, including unstable angina, myocardial infarction within the past 3 months, or heart failure.
•Uncontrolled diabetes mellitus.
•Uncontrolled hypertension.
•Active systemic infection requiring treatment.
•Women who are pregnant, possibly pregnant, within 28 days postpartum, or breastfeeding; men whose partners wish to become pregnant.
•Psychiatric disorders or symptoms that significantly interfere with daily life and make participation in this study difficult.
•Continuous systemic administration of corticosteroids (equivalent to >=10 mg prednisolone) or immunosuppressive drugs (oral or intravenous).
•Positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV Ab).
•Positive for HIV antibody.
•Interstitial pneumonia, pulmonary fibrosis, severe emphysema, or a combination of these diagnosed by chest CT.
•Administration of CBM588 within 5 days prior to informed consent.
•Participation in other clinical trials or studies.
•Any comorbidity or condition judged to interfere with treatment.

研究者

发起方

未提供

相似试验

已完成

1 期

A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.

2023-506661-65-00Bristol-Myers Squibb Services Unlimited Company40

尚未招募

3 期

Comparison between Rasapachak vati and Sahacharadi Tail Basti and Oral contraceptive pills and Metformin in PCOD patients

CTRI/2025/02/081328Dr Vidya Bhaskarrao Dole80

已完成

1 期

A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy participantsType 2 Diabetes

2023-503949-65-00Novo Nordisk A/S120

招募中

不适用

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (J2A-MC-GZPR)Peripheral Arterial Disease

jRCT20312505701,205

招募中

1 期

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies

2024-511453-22-00Kumquat Biosciences Inc.112